Dr. Jason Karlawish

Katrina Miller, a science reporter for The New York Times, discusses historic cuts to National Science Foundation funding, exploring the impact on research and the future of STEM initiatives. Accompanying her is Dr. Jason Karlawish, a Professor of Medicine at the University of Pennsylvania, who reveals a groundbreaking FDA-approved blood test for Alzheimer’s, which measures amyloid and tau proteins. Their conversation addresses not only the financial strain on science but also the exciting advancements in Alzheimer’s diagnosis that could change patient care.

Dr. Jason Karlawish, a renowned geriatrician and Alzheimer’s expert from the University of Pennsylvania, dives into the latest breakthroughs in Alzheimer’s medications like lecanemab and donanemab. They discuss how biomarkers revolutionize diagnosing Alzheimer’s and analyze the effectiveness of these new treatments. Ethical dilemmas surrounding lecanemab’s use are also explored, alongside the complexities families face in navigating care choices. Expect insights on the evolving landscape of Alzheimer’s research and pragmatic strategies for caregivers.

Join physician and Alzheimer's expert Jason Karlawish as he dives deep into the complexities of dementia and its impact on patients and caregivers. He discusses the critical differences between Alzheimer’s and dementia while highlighting the emotional toll on those providing care. Jason shares insights from his personal journey in geriatric medicine, emphasizing the need for a shift in how society perceives Alzheimer's. He also critiques systemic healthcare issues and advocates for meaningful support for affected families.